[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353590-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353590-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","deltahed-predicts-survival-and-immune-evasion-in-pd-1-blockade-therapy-a-multi-cohort-study-across-three-cancer-types","deltaHED predicts survival and immune evasion in PD-1 blockade therapy - A multi-cohort study across three cancer types","","Prognostic relevance of HLA class I (HLA-I)-mediated immunity in cancer immunotherapy remains incompletely defined. This study introduces deltaHED, a quantitative measure of germline–somatic HLA-I divergence loss, linking tumor-mediated HLA diversity reduction to immune escape. Across nasopharyngeal carcinoma, melanoma, and esophageal squamous cell carcinoma cohorts, high deltaHED aligns with poor outcome under PD-1 blockade and with mutation enrichment in antigen presentation and T-cell activation pathways. ",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/deltahed-predicts-survival-and-immune-evasion-in-pd-1-blockade-therapy-a-multi-cohort-study-across-three-cancer-types/353590/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/deltahed-predicts-survival-and-immune-evasion-in-pd-1-blockade-therapy-a-multi-cohort-study-across-three-cancer-types/353590.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does deltaHED measure in PD-1 blockade therapy?","Question",{"text":63,"@type":64},"deltaHED quantifies the difference between germline HED and somatic HED, capturing the extent of tumor-mediated loss of HLA-I diversity. Higher deltaHED indicates greater HLA diversity loss.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is immune evasion linked to somatic HED?",{"text":68,"@type":64},"Somatic HED reflects loss of heterozygosity in tumor cells, which reduces specific HLA allele availability and lowers antigen presentation. This reduced presentation contributes to immune evasion.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancer types were evaluated to validate deltaHED’s prognostic value?",{"text":72,"@type":64},"Validation spans nasopharyngeal carcinoma (NPC), melanoma, and esophageal squamous cell carcinoma (ESCC) cohorts, assessing survival and immune evasion under PD-1 blockade.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353590,1790558499,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","DOI: 10.1002/ctm2.70595  \nRESEARCH ARTICLE  \ndeltaHED predicts survival and immune evasion in PD-1 blockade therapy: A multi-cohort study across three cancer types  \nJianying Xu1,2  Xiaoli Wei1  Jicheng Yao3  Ujjwal Mukund Mahajan2, 4  Ulf Dietrich Kahlert5  Run Shi6  Kaiying Zhang1  Ahmed Alnatsha2  Zhengyi Qian1  Fei Han7  Fenghua Wang1  \n1 Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China  \n2 Department of Medicine II, LMU University Hospital, Munich, Germany  \n3 Research and Development Department, Shanghai OrigniMed Co., Ltd, Shanghai, China  \n4 Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India  \n5 Department of Molecular and Experimental Surgery, Clinic for General, Visceral, Vascular and Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany  \n6 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China  \n7 Departments of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China  \nCorrespondence  \nFei Han, Department of Radiation Oncology, SunYat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. [Email:](Email: hanfei@sysucc.org.cn)[ hanfei@sysucc.org.cn](Email: hanfei@sysucc.org.cn)  \nGraphical Abstract  \ndeltaHED predicts survival and immune evasion in PD-1 blockade therapy: a multi-cohort study across three cancer types. deltaHED quantifies germlinesomatic HLA-I divergence and predicts survival and immune evasion in PD-1 blockade therapy. Across nasopharyngeal carcinoma, melanoma, and esophageal squamous cell carcinoma, high deltaHED is associated with poor prognosis and increased mutations affecting antigen presentation and T-cell activation. (A) Germline HLA evolutionary divergence (HED) reflects the inherited diversity of human leukocyte antigen (HLA) alleles (e.g., HLA-A:01:01, HLAA:02:01, HLA-B:07:02, HLA-B:08:01, HLA-C:03:03, HLA-C:07:01), enabling the presentation of diverse immunogenic antigens (different colour in ball) and potential of broad T-cell activation. (B) Somatic HED: tumour cells undergo loss of heterozygosity (LOH), leading to the loss of specific HLA alleles (e.g., HLA-A:01:01 LOH, HLA-B :08:01 LOH, HLA-C:07:01 LOH) and reduced antigen presentation, resulting in immune evasion. (C) deltaHED (quantifying HLA diversity loss): deltaHED is calculated as the difference between germline HED and somatic HED, reflecting the extent of tumour-mediated HLA diversity loss. High deltaHED is associated with higher mutation percentage of antigen presentation pathway and poor survival in patients receiving PD-1 blockade therapy (validated in nasopharyngeal carcinoma [NPC], melanoma, and esophageal  \nClin. Transl. Med. 2026;16:e70595 .  \n[https://doi.org/10.1002/ctm2.70595](https://doi.org/10.1002/ctm2.70595)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nXU et al.  \nFenghua Wang, Department of Medical Oncology, SunYat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.  \n[Email:](Email: wangfh@sysucc.org.cn)[ wangfh@sysucc.org.cn](Email: wangfh@sysucc.org.cn)  \nsquamous cell carcinoma [ESCC] cohorts) . HLA alleles: red (HLA-A), blue (HLA-B), green (HLA-C) . T cells: green (activated), grey (inactivated) . The  \nabstract graph is created in [https://BioRender.com](https://BioRender.com).  \nDOI: 10.1002/ctm2.70595  \nRESEARCH ARTICLE  \ndeltaHED predicts survival and immune evasion in PD-1 blockade therapy: A multi-cohort study across three cancer types","cbCaio4yVGXlgxra","https://ap.wps.com/l/cbCaio4yVGXlgxra","pdf",1824902,12,"English","# Graphical Abstract\n## Germline HLA evolutionary divergence (HED)\n## Somatic HED and loss of heterozygosity (LOH)\n## deltaHED and predicted survival/immune evasion","[{\"question\":\"What does deltaHED measure in PD-1 blockade therapy?\",\"answer\":\"deltaHED quantifies the difference between germline HED and somatic HED, capturing the extent of tumor-mediated loss of HLA-I diversity. Higher deltaHED indicates greater HLA diversity loss.\"},{\"question\":\"How is immune evasion linked to somatic HED?\",\"answer\":\"Somatic HED reflects loss of heterozygosity in tumor cells, which reduces specific HLA allele availability and lowers antigen presentation. This reduced presentation contributes to immune evasion.\"},{\"question\":\"Which cancer types were evaluated to validate deltaHED’s prognostic value?\",\"answer\":\"Validation spans nasopharyngeal carcinoma (NPC), melanoma, and esophageal squamous cell carcinoma (ESCC) cohorts, assessing survival and immune evasion under PD-1 blockade.\"}]","deltaHED predicts survival and immune evasion in PD-1 blockade therapy - A multi-cohort study across three cancer types | PDF",1790106200,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1616ca486a17cfe684ade65d5f242596.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f13605825b8f24fc7a069fb5920b6087.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffc7ea4627256541b77602b0fbe88c85.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5d53f3d38512f891189f14b505d94b1.webp",980,1287]